Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PD-L1 up-regulation in melanoma increases disease aggressiveness and is mediated through miR-17-5p

9 Feb 2017

Abstract excerpt

// Valentina Audrito 1, 2, * , Sara Serra 1, 2, * , Aureliano Stingi 1, 2 , Francesca Orso 3 , Federica Gaudino 1, 2 , Cinzia Bologna 1, 2 , Francesco Neri 1 , Giulia Garaffo 3 , Romina Nassini 4 , Gianna Baroni 5 , Eliana Rulli 6 , Daniela Massi 5 , Salvatore Oliviero 1, 7 , Roberto Piva 3 , Daniela Taverna 3 , Mario Mandalà 8, ** , Silvia Deaglio 1, 2, ** 1 Human Genetics Foundation (HuGeF), Turin, Italy...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Immunotherapy and Immune Responses
Share to Melanoma and MAPK Pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28199980
DOI: 10.18632/oncotarget.15213

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PD-L1 up-regulation in melanoma increases disease aggressiveness and is mediated through miR-17-5pPMID 28199980Read ↗

PD-L1 marks a subset of melanomas with a shorter overall survival and distinct genetic and morphological characteristicsSemantic proximity Read ↗

Transcriptome-Wide Association Study Reveals New Molecular Interactions Associated with MelanomaSemantic proximity Read ↗

Transcriptional reprogramming and constitutive PD-L1 expression in melanoma are associated with dedifferentiation and activation of interferon and tumor necrosis factor signaling pathwaysSemantic proximity Read ↗

Recent Progress in Mutation-driven Therapy, Immunotherapy and Combination Therapy for the Treatment of Melanoma.Semantic proximity Read ↗

Companion diagnostics and predictive biomarkers for PD-1/PD-L1 immune checkpoint inhibitors therapy in malignant melanoma.Semantic proximity Read ↗

Transcriptional Reprogramming and Constitutive PD-L1 Expression in Melanoma Are Associated with Dedifferentiation and Activation of Interferon and Tumour Necrosis Factor Signalling PathwaysSemantic proximity Read ↗

Programmed Cell Death Ligand 1 Immunohistochemical Expression and Cutaneous Melanoma: A Controversial RelationshipSemantic proximity Read ↗

Molecular biology of normal melanocytes and melanoma cells.Semantic proximity Read ↗

Programmed cell death‐1 blockade therapy in melanoma: Resistance mechanisms and combination strategiesSemantic proximity Read ↗

Prognostic and predictive biomarkers in melanoma: an updateSemantic proximity Read ↗

Roads to melanoma: Key pathways and emerging players in melanoma progression and oncogenic signalingSemantic proximity Read ↗

p53-related pathways and the molecular pathogenesis of melanomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.